[Pharmacokinetics of XXXX in @entity409 ].

@entity1 @entity409 @entity5898 @entity3194 @entity157 @entity7434 @entity58145 @entity2891 @entity5579
To obtain useful informations for determining the optimal dosage of drugs in @entity1 with @entity409 , pharmacokinetics of @entity2891 ( @entity5579 ) was studied in healthy adults (normal control group) and 35 @entity1 with @entity409 ( @entity409 group). @entity5579 is a new third generation @entity5898 which is mainly excreted into the bile and has serum half-life of about 2 hours. After a rapid intravenous injection of @entity5579 , peripheral blood and urine samples were obtained at the time according to the protocol of this study. Serum and urine concentrations of @entity5579 were determined by the bioassay method using @entity58145 as the test strain. From the concentrations of @entity5579 in serum and urine, pharmacokinetic parameters were calculated by means of a "two-compartment open model". After an administration of @entity5579 , the serum concentration declined more slowly in the @entity409 group as compared to the normal control group. At 1 hour after intravenous injection of @entity5579 , the difference of the serum level was already observed between these 2 groups. The half-life of elimination (T 1/2) was 2 to 4 times longer in the @entity409 group. The elimination rate constant ( @entity7434 ) and total clearance (Clt) of @entity5579 were much lower in the @entity409 group than in the control group except for @entity157 . On the other hand, urinary excretion rate (Ur) was lower in the normal control group than in the @entity409 group. There was a close correlation between disappearance rate of @entity3194 (KICG) and parameters such as T1/2, @entity7434 , Clt and Cler with coefficients of -0.642, 0.723, 0.690 and 0.682, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
